Finepoint Capital LP Crinetics Pharmaceuticals, Inc. Transaction History

Finepoint Capital LP

  • $963 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
SELL
$15.73 - $23.6 $1.12 Million - $1.67 Million
-70,900 Reduced 8.16%
797,527 $14.4 Million
Q1 2023

May 12, 2023
BUY
$15.31 - $21.1 $699,391 - $963,890
45,682 Added 5.55%
868,427 $13.9 Million
Q4 2022

Feb 13, 2023
BUY
$15.49 - $19.05 $12.7 Million - $15.7 Million
822,745 New
822,745 $15.1 Million

Others Institutions Holding CRNX

# of Institutions
241
Shares Held
79.6M
Call Options Held
23.3K
Put Options Held
44.3K
View Full List

About Crinetics Pharmaceuticals, Inc.

CRNX Quotes by TradingView
  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Finepoint Capital LP Portfolio

Follow Finepoint Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Finepoint Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email